Outlook Therapeutics (OTLK) CFO Kevin Lundquist Receives 500K Option Award

What Happened Kevin Michael Lundquist, Chief Financial Officer of Outlook Therapeutics, was granted a derivative award (described in the filing as an option) for 500,000 shares on 2026-09-01. The grant is reported at a $0.00 price, so the Form 4 shows $0 total value for the transaction. This is a grant/award (not an open-market purchase or sale).

Key Details

• Transaction date: 2026-09-01; Form 4 filed 2026-09-02 (timely filing).
• Award: 500,000-share option reported at $0.00 (derivative).
• Shares owned after transaction: Not disclosed in the provided filing excerpt.
• Footnote: Grant was made as an inducement to Lundquist's entry into employment per Nasdaq Listing Rule 5635(c)(4). Vesting: 25% vests on Sept 1, 2027, then the remaining 75% vests in equal monthly installments over the following three years, subject to continued service.
• No 10b5-1 plan, tax-withholding sale, or late-filing indication shown in the excerpt.

Context This is an employment inducement option grant rather than a market purchase or sale; such grants are common when hiring senior executives and are intended to align incentives over time via vesting. The $0.00 reporting reflects the award/derivative nature on the Form 4 and does not provide a market valuation of the underlying economic value.